Anti-granulocyte-macrophage colony-stimulating factor antibody otilimab in patients with hand osteoarthritis: a phase 2a randomised trial

骨关节炎 粒细胞巨噬细胞集落刺激因子 医学 抗体 内科学 粒细胞 免疫学 病理 细胞因子 替代医学
作者
Georg Schett,L. C. Bainbridge,Mario Berkowitz,Katherine Davy,Sofia Fernandes,E.N. Griep,Stephen A. Harrison,Anubha Gupta,James Lloyd‐Hughes,Andy D. Roberts,Mark Layton,Nonna Nowak,Jatin Patel,Jürgen Rech,Julia E. Smith,Sarah Watts,Paul P. Tak
出处
期刊:The Lancet Rheumatology [Elsevier]
卷期号:2 (10): e623-e632 被引量:11
标识
DOI:10.1016/s2665-9913(20)30171-5
摘要

Background Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a key mediator of signs and symptoms in preclinical models of osteoarthritis. We explored the efficacy, safety, and pharmacokinetics of an anti-GM-CSF antibody, otilimab, in patients with hand osteoarthritis. Methods This double-blind, randomised, placebo-controlled phase 2a study was done in 16 centres in the Netherlands, Germany, Poland, the UK, and the USA. Patients aged 18 years or older with inflammatory hand osteoarthritis, who had received at least one course of unsuccessful non-steroidal anti-inflammatory drugs, with two or more swollen and tender interphalangeal joints (on the same hand), signs of inflammation or synovitis identified with MRI in the affected hand, and a self-reported 24 h average hand pain intensity over the past 7 days of 5 or more on a 0–10 numerical rating scale were eligible for inclusion. Patients were randomly assigned (1:1) via interactive response technology (blocked randomisation; block size of four) to receive either subcutaneous otilimab 180 mg or placebo, administered weekly from week 0 to week 4, then every other week until week 10. Patients, investigators, and trial staff were masked to treatment; at least one administrator at each site was unmasked to prepare and administer treatment. The primary endpoint was change from baseline in 24 h average hand pain numeric rating scale averaged over 7 days before the visit at week 6. Secondary endpoints were: change from baseline in 24 h average and worst hand pain intensity at each visit; proportion of patients showing 30% and 50% reductions in 24 h average and worst hand pain intensity at each visit; change from baseline in Australian and Canadian Hand Osteoarthritis Index (AUSCAN) 3·1 numeric rating scale questionnaire components at each visit; change in number of swollen and tender hand joints at each visit; change from baseline in Patient and Physician Global Assessment of disease activity; serum concentration of otilimab; and safety parameters. Efficacy endpoints were assessed in the intention-to-treat population. The safety population included all patients who received at least one dose of study treatment. The study is registered with ClinicalTrials.gov, NCT02683785. Findings Between March 17, 2016, and Nov 29, 2017, 44 patients were randomly assigned (22 in the placebo group and 22 in the otilimab group). At week 6, difference in change from baseline in 24 h average hand pain numeric rating scale between the otilimab and placebo groups was −0·36 (95% CI −1·31 to 0·58; p=0·44); at week 12, the difference was −0·89 (–2·06 to 0·28; p=0·13). Patients receiving otilimab showed greater improvement in AUSCAN components versus placebo at each visit. The change from baseline in the 24 h worst hand pain numeric rating scale in the otilimab group at week 6 showed a difference over placebo of −0·33 (95% CI −1·28 to 0·63; p=0·49); at week 12, this difference was −1·01 (95% CI −2·22 to 0·20; p=0·098). The proportion of patients achieving 30% or higher or 50% or higher reduction from baseline in the 24 h average and worst hand pain numeric rating scale scores was consistently greater (although non-significant) with otilimab versus placebo. Similarly, patients receiving otilimab showed greater improvement in AUSCAN pain, functional impairment, and stiffness scores versus placebo at each visit. No differences were observed between otilimab and placebo in the change from baseline in the number of swollen and tender joints across the study. The Patient Global Assessment was consistently lower than placebo at all visits; the Physician Global Assessment showed reductions across the study period, but the changes were similar in both treatment groups. Median otilimab serum concentrations increased during weekly dosing from 1730 ng/mL at week 1 to a maximum of 3670 ng/mL at week 4, but declined after transitioning to dosing every other week (weeks 6–10). In total, 84 adverse events were reported by 24 patients: 54 adverse events in 13 (59%) patients in the otilimab group and 30 adverse events in 11 (50%) patients in the placebo group. The most common adverse events were cough (reported in 4 [9%] patients; 2 in each group), and nasopharyngitis (in 3 [7%] patients; 1 in the placebo group and 2 in the otilimab group). Three serious adverse events occurred in this study (all in the otilimab group) and were deemed not related to the study medication. There were no deaths during the study. Interpretation There was no significant difference between otilimab and placebo in the primary endpoint, although we noted a non-significant trend towards a reduction in pain and functional impairment with otilimab, which supports a potential role for GM-CSF in hand osteoarthritis-associated pain. There were no unexpected safety findings in this study, with no treatment-related serious adverse events reported. Funding GlaxoSmithKline.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
完美修杰完成签到,获得积分20
刚刚
滕老板发布了新的文献求助10
1秒前
淡然子轩完成签到,获得积分10
2秒前
从容芮应助cheesy采纳,获得10
4秒前
123完成签到,获得积分10
5秒前
汉堡包应助犯困小黄人采纳,获得10
7秒前
大模型应助园圆采纳,获得10
7秒前
dylaner完成签到,获得积分10
10秒前
英姑应助勇者先享受生活采纳,获得10
14秒前
卷心菜包饭完成签到,获得积分10
16秒前
FOREST发布了新的文献求助10
16秒前
19秒前
赘婿应助科研通管家采纳,获得10
19秒前
科研通AI2S应助科研通管家采纳,获得10
19秒前
情怀应助科研通管家采纳,获得10
19秒前
搜集达人应助科研通管家采纳,获得10
19秒前
zanebono完成签到,获得积分10
19秒前
科研通AI2S应助科研通管家采纳,获得10
19秒前
xiaoming应助科研通管家采纳,获得10
19秒前
Lucas应助科研通管家采纳,获得10
19秒前
0128lun应助科研通管家采纳,获得10
19秒前
19秒前
科研通AI2S应助科研通管家采纳,获得10
19秒前
所所应助科研通管家采纳,获得10
19秒前
20秒前
悦耳的绿旋完成签到,获得积分10
21秒前
22秒前
cheesy完成签到,获得积分10
22秒前
所所应助Jiaxin_Li采纳,获得10
24秒前
czzlancer完成签到,获得积分10
24秒前
25秒前
ahaaa发布了新的文献求助10
25秒前
28秒前
30秒前
hope完成签到,获得积分10
34秒前
西番雅发布了新的文献求助10
36秒前
小猪完成签到 ,获得积分10
37秒前
123456发布了新的文献求助10
37秒前
沧海医僧笑完成签到,获得积分20
37秒前
38秒前
高分求助中
Sustainability in Tides Chemistry 2800
Kinetics of the Esterification Between 2-[(4-hydroxybutoxy)carbonyl] Benzoic Acid with 1,4-Butanediol: Tetrabutyl Orthotitanate as Catalyst 1000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Very-high-order BVD Schemes Using β-variable THINC Method 568
Chen Hansheng: China’s Last Romantic Revolutionary 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3138572
求助须知:如何正确求助?哪些是违规求助? 2789520
关于积分的说明 7791526
捐赠科研通 2445903
什么是DOI,文献DOI怎么找? 1300715
科研通“疑难数据库(出版商)”最低求助积分说明 626058
版权声明 601079